18
total announcements
539730.BO · 15 min delayed
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 3,61,599 equity shares to non-promoter allottees pursuant to the conversion of 1,20,533 warrants into equity shares, consequent to the 1:2 bonus issue.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 3,61,599 equity shares to non-promoter allottees pursuant to the conversion of 1,20,533 warrants into equity shares, consequent to the 1:2 bonus issue.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has acquired a 26% stake in Goodman Vetcare Pvt. Ltd, a ₹300 Crore-valued pet pharmacy, to accelerate Goodman's growth and become India's largest pet-care retail chain over the next five years.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 271,200 equity shares upon conversion of warrants to non-promoter investors, with the allotment made in dematerialized form and the shares ranking pari passu with existing equity shares.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has allotted 2,71,200 equity shares to non-promoters upon conversion of warrants into equity shares, as per the approval of shareholders in their Extra-Ordinary General Meeting held on October 22, 2025.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd announces the launch of PAWTALKS, a platform for conversations on pet and animal healthcare, aiming to bring together experts and pet parents for knowledge sharing and informed decision-making.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has been permitted to trade and admitted to dealings on the National Stock Exchange of India Limited (NSE) with effect from August 17, 2026.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd reported Q1 FY27 results with a 90.44% YoY growth in standalone total income to INR228.25 crores, EBITDA growth of 92.90% YoY to INR32.78 crores, and net profit growth of 94.63% YoY to INR13.17 crores. The company expects 35-30% blended growth for the next 3 years and 25-35% growth for its domestic business over the next 5 years.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has filed a statement of deviation or variation for the quarter ended June 30, 2026, under Regulation 32(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has confirmed that there was no deviation or variation in the utilisation of proceeds raised through Preferential Issue. The Monitoring Agency Report dated August 14, 2026, issued by Care Ratings Limited, has been placed before the Audit Committee and Board at their meeting held on August 14, 2026.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has submitted a Monitoring Agency Report dated 14.08.2026, as per SEBI Regulations, regarding the utilization of proceeds raised through Preferential Allotment for the quarters ended March 31, 2026 and June 30, 2026. The report highlights deviations from the objects of the issue, including loan payments, asset purchases, and tax payments, which were not explicitly covered in the definition of the various objects.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has made the audio recording of its Q1 FY27 earnings conference call available on its website.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd will host an earnings conference call on August 13, 2026, to discuss Q1 FY27 results.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has published un-audited financial results for the quarter ended 30th June, 2026, as approved by the Board in its meeting held on 05th August, 2026.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has published un-audited financial results for the quarter ended 30th June, 2026, as approved by the Board in its meeting held on 5th August, 2026. The results were published in newspapers on 6th August, 2026.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced its unaudited financial results for Q1 FY27, with revenue jumping 90%, EBITDA surging 93%, and profit rising 95% YoY. The company has also allotted 1.10 crore Bonus Equity Shares in a 2:1 ratio to eligible shareholders.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced the outcome of its Board Meeting, which included the adoption and approval of the un-audited financial results for the quarter ended June 30, 2026, along with a limited review report by its statutory auditor.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, along with a limited review report from its statutory auditor, M/s. R.H. Nisar & Co. The trading window for insiders closed on July 1, 2026, and the board meeting commenced at 10:30 a.m. and concluded at 11:20 a.m.
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 05/08/2026 to consider and approve the Unaudited Financial Results for the first quarter ended 30/06/2026.